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Abstract
Background: The amount of urinary glycoprotein lipocalin 2 (LCN2) has been known to increase after kidney injury
because of failed reabsorption by the proximal tubules or direct secretion from injured tissues. However, the
relationship between urinary tract obstruction and the isoform diversity of LCN2 has not been examined.
Methods: The urinary levels of LCN2 isoforms were examined in male mice after an intraperitoneal injection
of lipopolysaccharide (LPS) or in a mouse model of unilateral ureter obstruction (UUO). The LCN2 levels in
sera, bladder urine, renal pelvic urine, and tissue samples were also analyzed. Endo- and exoglycosidases were
used to investigate the different N-glycan patterns of LCN2.
Results: Two isoforms of urinary LCN2 with different molecular weights were identified in an immunoblotting
analysis, and the levels of both isoforms were increased 6 h after LPS administration. The primary LCN2 isoform
was the lower molecular weight 22-kDa isoform, which was detected in the serum, urine, liver and kidney. In
contrast, the 24-kDa LCN2 isoform was detected only in urine. In the UUO experiments, the levels of the 24-kDa
LCN2 were increased in the bladder urine but not in the urine accumulated in the renal pelvis due to UUO. The
22-kDa LCN2 was identified in the renal pelvic urine from UUO mice. The peptide-N glycosidase F digestion of
the two urinary LCN2 isoforms generated a single protein. Moreover, the two urinary LCN2 proteins were sensitive to
neuraminidase and resistant to endoglycosidase H (Endo H). The LCN2 in the serum, lung and kidney was resistant to
Endo H, as observed in urine, whereas the LCN2 in the liver and the ureter were degraded by this enzyme.
Conclusions: These results suggest that the difference in the molecular weights of the LCN2 proteins was due to their
N-glycan structure. The high molecular weight LCN2 in urine could be detected after the inflammatory response to LPS
and UUO. Furthermore, the sensitivity to Endo H identified the presence of two types of carbohydrate moieties,
depending on the tissue in which the LCN2 was produced. These findings are useful for widening the clinical
applicability of urinary LCN2 analyses.
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Background
Lipocalins constitute a family of small secreted proteins
with a common structure, primarily consisting of an
eight-stranded beta-sheet, that form hydrogen-bonded
beta-barrels [1]. The members of this family serve dif-
ferent functions by binding to small hydrophobic li-
gands and play an important role in regulating the
immune system activity [1]. Lipocalin 2 (LCN2), which
is also called neutrophil gelatinase-associated lipocalin
(NGAL) or 24p3, has been identified in a variety of
samples, including neutrophils, uterine luminal fluid,
and SV40-infected primary kidney cells [2–4]. Many
lipocalins act as a carrier for specific proteins and fatty
acids, and the LCN2 proteins can form complexes with
catecholate-type siderophores, such as enterochelins,
which are small iron-containing molecules [5]. These
LCN2-iron complexes bind to cell surface receptors to
transport iron into the cell [6]. The sequestration of
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iron by LCN2 could play a protective role in the innate
immune response against bacterial infections and may
be involved in cellular processes, such as the induction
of apoptosis [5–7].
During the acute phase response, LCN2 is significantly
upregulated [8]. It has been investigated as a non-
invasive biomarker for a variety of diseases, including
inflammation and acute kidney injury [9–12]. Under
physiological conditions, expression of the Lcn2 gene
can be detected in the trachea, bone marrow, colon,
lungs, prostate, and uterus in humans [4, 13]. However,
Lcn2 gene expression and protein synthesis are en-
hanced in various cells under stressful conditions, such
as cancer, acute kidney or liver injury, infection, and
ulcerative colitis [9, 14–17]. The bacterial endotoxin LPS
induces the transcription of Lcn2 via toll-like receptor 4
[18]. Additionally, LPS often induces a variety of cyto-
kines [19–21]. Proinflammatory cytokines, including
interleukin-1β (IL-1β) and IL-17, in combination with
tumor necrosis factor α (TNFα), can facilitate the pro-
moter activity of the Lcn2 gene [17, 22–24]. These cyto-
kines activate the transcription factor nuclear factor-kappa
B (NF-κB) by stabilizing the cofactor IκB-ζ transcript,
which is essential for the induction of Lcn2 gene transcrip-
tion [22, 24].
The LCN2 proteins produced at sites of inflammation
are rapidly secreted into the systemic circulation, pass
through the glomeruli, and are completely reabsorbed
by renal proximal tubular cells via the scavenger-
receptor megalin and cubilin-dependent endocytosis
[25–28]. Increased urinary LCN2 levels suggest prox-
imal tubule dysfunction, which contributes to failed
urinary LCN2 reabsorption, or the de novo synthesis of
LCN2 in the injured kidney [29, 30]. For example,
Kuwabara et al. reported that an increase in urinary LCN2
in streptozotocin-induced diabetic mice was caused by a
dysfunction of tubular reabsorption, and elevated serum
LCN2 levels were considered to be a source of urinary
LCN2 [27]. Predicting the origin of urinary LCN2 may
help to identify proximal tubule dysfunction distinct from
direct injury of the urinary tract, but such knowledge is
limited at present.
We previously established an animal model of drug-
induced kidney injury, which was accompanied by
urinary LCN2 elevation [31]. In the present study, we
characterized two subpopulations of LCN2 with dis-
tinct molecular weights, 22- and 24-kDa LCN2, in the
urine from model mice with LPS-induced inflammation
or ureteral obstruction. Because LCN2 is a member of
the glycoprotein family [4, 32], the 24-kDa urinary LCN2
was expected to be more glycosylated than 22-kDa LCN2.
In the current study, our deglycosylation analysis revealed
that the LCN2 in the serum, urine, and peripheral tissues
exhibited different N-glycan patterns in LPS-treated mice.
Moreover, the 24-kDa form of LCN2 could be detected in
urine from mice with experimental unilateral ureteral ob-
struction. Our results suggest that the characterization of
the glycoforms of LCN2 may help to narrow down their
origin, and it may be possible to link certain glycoforms of
LCN2 to specific organ dysfunction.
Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), LPS (E. coli
O128:B12), and dexamethasone (Dex) were obtained from
Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine
serum, antibiotics, and cloning vectors were purchased
from Life Technologies (Carlsbad, CA, USA). HEK293
cells were obtained from the American Type Culture Col-
lection (Manassas, VA, USA). The anti-mouse LCN2 anti-
body was purchased from Abnova (Taipei, Taiwan).
Goat anti-rabbit IgG was obtained from GE Healthcare
Life Sciences (Buckinghamshire, UK). Complete Mini,
EDTA-free protease inhibitor cocktail was from Roche
(Mannheim, Germany). The DNA ligation kit and EX
Taq were purchased from Takara Bio (Shiga, Japan).
PNGase F, Endo H, and Neuraminidase (NA) were ob-
tained from New England BioLabs (Herts, UK). Coomas-
sie brilliant blue (CBB) solution and the Rapid Stain CBB
kit were procured from Nacalai Tesque (Kyoto, Japan). All
other chemicals were purchased from Wako Pure Chem-
ical Industries (Osaka, Japan).
Animals
Male and female BALB/c CrSlc and male C57BL/6J
JmsSlc mice were obtained from SLC Japan (Shizuoka,
Japan). All animals used in this study were eight weeks
old. The mice were housed in micro-isolator cages in a
pathogen-free barrier facility (12 h light: 12 h darkness
cycle) with access to regular chow and water ad libitum.
All animal experiments were approved by the Animal
Care and Use Committee of Jichi Medical University.
Drug administration
Male and female BALB/c CrSlc and male C57BL/6J
JmsSlc mice were intraperitoneally (i.p.) injected with
1 mg/kg of LPS. Saline was administered as a control.
Dex (5 mg/kg) or vehicle (saline) was administered i.p.
1 h prior to LPS. After 6 h, the mice were euthanized
by cervical dislocation, and trunk blood samples were
collected and allowed to clot for 30 min at room
temperature, followed by centrifugation at 3000 × g for
10 min to obtain serum. The tissues were sampled and
homogenized in lysis buffer (50 mM Tris–HCl
(pH 7.4), 150 mM NaCl, 1 % Nonidet P40, 1 mM EDTA
(pH 8.0), 1 mM EGTA, and 1 mM phenylmethylsulfo-
nyl fluoride) containing a protease inhibitor cocktail
and were centrifuged at 12,000 × g for 5 min to collect
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the supernatant. The protein concentrations were mea-
sured using the CBB method. Spot urine samples were
collected and immediately placed on ice, and urine,
serum, and tissue lysates were stored at −80 °C until
further use. For the measurement of the serum C-
related protein (CRP) level, serum samples were diluted
2000–20,000-fold and CRP and IL-1β levels were mea-
sured using ELISA kits (R & D Systems, Minneapolis,
MN, USA). The absorbance at 450 nm and 540 nm
was measured using a SpectraMax Pro M3 instrument
(Molecular Device, CA, USA).
UUO experiments
For the UUO experiments, the mice were anesthetized
with 50 mg/kg of pentobarbital sodium i.p. After lapar-
otomy, the left ureter was ligated with a silk suture (5–
0) 0.7 cm below the renal pedicle. Three days later, the
mice were euthanized by cervical dislocation, then their
urine, which accumulated in the obstructed side of the
kidney and bladder, was sampled by syringe aspiration
with 30 G 1/2 and 26 G 1/2 needles. Control mice
underwent a sham operation (the ureter was manipu-
lated but not ligated). Urine samples were kept at −80 °C
until use.
Preparation of recombinant mouse LCN2
The coding sequence for mouse LCN2 cDNA was ampli-
fied from brain cDNA by PCR using Ex Taq reagents. The
primer sequences used to amplify mouse Lcn2 were 5′-
AAACCATGGCCCTGAGTGTCAT-3′ and 5′-GCCTGA
ACCATTGGGTCTCTGC-3′. The PCR products were
subcloned into the pCR-4 vector according to the man-
ufacturer’s protocol and sequenced. The mouse LCN2
cDNA was then ligated into the pcDNA3.1 expression
vector. Human embryonic kidney (HEK293) cells were
cultured in a six-well dish with DMEM containing 10 %
heat-inactivated fetal bovine serum, 100 U/ml penicil-
lin, and 100 μg/ml streptomycin at 37 °C in 5 % CO2.
Plasmid DNA was transfected into HEK293 cells with
the FuGENE HD transfection reagent (Promega, Madison,
WI) following the manufacturer’s protocol. The culture
media were exchanged to serum-free media 24 h after
transfection and was collected 48 h after transfection. Five
hundred microliters of culture medium were further
centrifuged at 14,000 × g for 10 min at 4 °C for concen-
tration and was replaced with phosphate-buffered saline
(PBS) using Amicon Ultra Centrifugal Filter Devices
(10 K molecular weight cutoff, Millipore, Billerica, MA,
USA). The buffer exchange was repeated three times.
The concentrated media, the final volume of which was
approximately 60 μL, were prepared for immunoblot
and glycosylation analyses.
Gel electrophoresis and immunoblotting
Protein samples were heated with sodium dodecyl sul-
fate (SDS) buffer (10 % glycerol, 2.3 % SDS, 5 % 2-
mercaptoethanol, 62.5 mM Tris–HCl (pH 6.8), and
0.1 % bromophenol blue) at 100 °C for 5 min. Spot
urine (2 μg of protein), tissues (5 μg), sera (5 μg), and
glycosidase-digested samples (5 μg of proteins and 2 μL
of concentrated-conditioned media) were electropho-
resed on 12.5 % SDS-polyacrylamide gels and trans-
ferred to polyvinylidene difluoride membranes. Urine
samples from UUO mice (2 μL of urine from the renal
pelvis and 5 μg of bladder urine (approximately 5–
10 μL)) were also subjected to electrophoresis. After
blocking (Block Ace; DS Pharma Biomedical, Osaka,
Japan) for 1 h at room temperature, the membranes
were incubated with a rabbit polyclonal antibody spe-
cific for mouse LCN2, which was diluted 1:8000 with
Can Get Signal Immunoreaction Enhancer Solution
(TOYOBO, Osaka, Japan) overnight at 4 °C. After incu-
bation for 1 h at room temperature with horseradish
peroxidase-labeled goat anti-rabbit IgG, which was di-
luted 1:10,000 as a secondary antibody, the membranes
were treated with ECL Western blotting detection re-
agents (Perkin Elmer Life Sciences, Boston, MA) and
visualized with a LAS-3000 fluorescence imaging sys-
tem (Fuji Film, Tokyo, Japan).
Quantitative analysis for gene expression
Tissue samples were isolated from LPS-treated male
BALB/c mice, and total RNA was extracted using TRIzol
reagent (Life Technologies, Carlsbad, CA). To synthesize
first-strand cDNA, 0.5 μg of total RNA was reverse tran-
scribed with the PrimeScript RT reagent kit (Takara Bio,
Shiga, Japan) per the manufacturer’s protocol. Gene-
specific primers were used for quantitative real-time PCR
as follows: mouse Lcn2–5′-CTGAATGGGTGGTGAGTG
TG-3′ for the left primer and 5′-GGGAGTGCTGGC-
CAAATAAG-3′ for the right primer; mouse β-actin–5′-
TTGCTGACAGGATGCAGAAG-3′ for the left primer
and 5′-ACATCTGCTGGAAGGTGGAC-3′ for the right
primer. The reactions were performed on a Dice Thermal
Cycler using SYBR Premix Ex Taq II (Takara Bio, Shiga,
Japan). The expression levels of β-actin were used as an
internal control.
Glycosylation analysis
Sera, urine, concentrated conditioned media, tissue sam-
ples, and proteins used as positive controls (fetuin and
RNase B) were treated with PNGase F, Endo H, or NA
according to the manufacturer’s instructions. PNGase F
hydrolyzes between the innermost N-acetylglucosamine
(GlcNAc) and Asn residues of all types of N-glycan. Endo
H cleaves between the two GlcNAc residues of the chito-
biose core of hybrid- or high mannose-type N-glycan, and
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NA digests the terminal N-acetyl-neuraminic acid resi-
dues from carbohydrates [33, 34]. Ten micrograms of pro-
tein and 9 μL of conditioned media were glycosidase
digested overnight at 37 °C. The samples were then boiled
in SDS-sample buffer for 5 min and analyzed by immuno-
blotting. SDS-polyacrylamide gels loaded with fetuin and
RNase B were stained with CBB after electrophoresis.
Quantitative image analysis and statistical analysis
The images were analyzed using the ImageJ gel analysis
software program (http://imagej.nih.gov/ij/). The data are
expressed as the mean ± S.E.M. Significant differences
were evaluated using an unpaired t-test or two-way
ANOVA. For multiple comparisons, P values were ad-
justed by Holm’s method. P < 0.05 was considered
significant.
Results
Detection of the two forms of LCN2 in urine
Previous studies reported that LPS challenge drastically
increased the LCN2 expression at the protein and
mRNA levels in the rat lung, liver, and kidney, as well as
in the mouse lung and liver [35, 36]. Our present work
also showed that LPS administration increased the
LCN2 mRNA and protein expression in the ureter and
bladder, as well as in the lung, liver and kidney of the
BALB/c mice (Fig. 1). Figure 1a shows a representative
result demonstrating two different isoforms of urinary
LCN2. Urinary LCN2 was hardly detectable under basal
conditions, but was detectable as a signal of apparently
stronger intensity compared with that of serum LCN2
after the administration of LPS (Fig. 1b and c). While
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Fig. 1 Detection of LCN2 in the urine from LPS-treated mice. Representative results of a Western blot analysis of the urinary LCN2 from
LPS-treated mice (a). Male BALB/c mice were treated with (b) saline or (c) LPS (1 mg/kg i.p.) for 6 h. Tissue, serum, and urinary protein samples of 5 μg
were subjected to Western blot analyses. Lu: lung, Li: liver, Ki: kidney, Ure: ureter, Bl: bladder, Se: serum, and Uri: urine. The numbers on the right sides
of the figures indicate the molecular size of LCN2 (kDa). n = 6–8 for saline, and n = 8–10 for LPS treatment. (d) The LCN2 mRNA expression
levels in peripheral tissues. The expression was normalized relative to that of β-actin, which served as an internal control. n = 5–7 for saline, and n = 4–
5 for LPS treatment. Error bars represent the S.E.M. ** P < 0.01, and *** P < 0.001
Fujiwara et al. Journal of Inflammation  (2016) 13:7 Page 4 of 10
was a single band with a molecular weight of 22 kDa,
the urinary LCN2 proteins in these mice showed two
forms with different molecular weights, i.e., 22 and
24 kDa (Fig. 1c).
In peripheral tissues, the majority of the upregulated
LCN2 was approximately 22 kDa in size. Faint LCN2-
immunopositive signals, which were slightly larger than
the 24-kDa urinary LCN2, were also detected in the liver
and ureter in the saline-injected mice. However, LPS did
not increase the densities of this band in either type of
sample. The single and double bands of LCN2 in the
serum and urine, respectively, were also observed in
LPS-treated female BALB/c and male C57B6 mice, indi-
cating that the sample-specific molecular patterns of
LCN2 proteins did not exhibit sex- or strain-specific
differences (data not shown). These results suggest that
the urinary LCN2 in LPS-treated mice consists of two
distinct molecular weight forms. Notably, the 24-kDa
LCN2 was upregulated in the urine, but not in the
serum, by LPS treatment.
The temporal expression of urinary LCN2 proteins
Because the 24-kDa LCN2 protein was specifically ob-
served in the urine of LPS-treated mice, we hypothesized
that it may serve as a biomarker to identify urinary tract
disorders. To prove this hypothesis, we established UUO
mice as a model of a urinary tract disorder. To search
for the origin of the 24-kDa LCN2 in urine, we per-
formed Western blot analyses of serum, urine and tissue
samples from these model mice. In the UUO experi-
ments, unilateral ureteral ligation successfully upregu-
lated the 22-kDa LCN2 expression on the obstructed
side of the ureter without affecting the opposite side
(Fig. 2). An immunopositive signal for 24-kDa LCN2
was barely detectable in both ureters of sham-operated
and UUO mice. The serum level of the 22-kDa LCN2
was increased in UUO mice. Despite the faint LCN2
band at 24 kDa, a robust signal for LCN2 was detected
at 22 kDa in the urine that had pooled in the renal pelvis
(Fig. 2). Interestingly, the 24-kDa LCN2 was observed
only in the bladder urine of UUO mice, with signifi-
cant differences in the signal-to-noise ratio (1.06 ±
0.012 for the sham operation, n = 6, and 1.35 ± 0.037
for UUO, n = 10, P = 0.047 based on an unpaired t-test).
These results suggest that a urinary tract obstruction
upregulates the urinary 24-kDa LCN2 level, which is
predominantly found in bladder urine.
Two glycosylation patterns of urinary LCN2
Because a previous study reported that mouse LCN2
contains two N-glycosylation sites in its amino acid se-
quence [4], we postulated that the two LCN2 forms with
different molecular weights observed in our experiment
were the result of post-transcriptional N-glycosylation.
The positive control assays in which fetuin and RNase
B were added as substrates for the endo- or exoglycosi-
dase showed enzymatic activity (Fig. 3a). Using urinary
LCN2 from LPS-treated mice as a substrate, PNGase F
digestion produced a single molecular weight protein
(Fig. 3b). The product size of the PNGase F-digested
urinary LCN2 was nearly equal to the molecular weight
of unglycosylated-recombinant mouse LCN2, i.e., 20 kDa
(Fig. 3c). The two forms of urinary LCN2 proteins
remained unaffected by Endo H, suggesting that the
urinary LCN2 proteins had neither high-mannose nor
hybrid type N-glycan (Fig. 3b). In addition, neuraminid-
ase (NA), which digests terminal N-acetyl-neuraminic
acid residues from carbohydrates, shifted the immunopo-
sitive bands of each urinary LCN2 to a lower molecular
weight. These results indicate that the 22- and 24-kDa
proteins observed in the Western blotting analysis con-
tained the same LCN2 protein and complex-type N-
glycan with terminal N-acetyl-neuraminic acid, but the
structures of their carbohydrate moieties differed.
The glycosylated forms of the LCN2 proteins in the
peripheral tissues
When mice were treated with LPS, increases in the
levels of LCN2 (at approximately 22 kDa) were detected
in the peripheral tissues (Fig. 1). Interestingly, the mo-
lecular weight of the LCN2 expressed in peripheral tis-
sues subtly differed among tissues. For example, the
mass of LCN2 was slightly higher in the lung than in the






Fig. 2 Detection of two LCN2 glycosylated forms in urine after three
days of UUO. Representative images showing the LCN2 protein
expression in the right (obstructed) and left (intact) ureters, sera,
and urine samples collected from the obstructed side of the renal pelvis
or bladder in UUO mice. Each experiment was repeated six times
for the sham operation and 10 times for the UUO mice. Ure-R, right
ureter; Ure-L, left ureter; Se, serum; p-U, urine in renal pelvis; and b-U,
bladder urine. The numbers on the right side of the figures indicate
the molecular size of LCN2 (kDa). Renal pelvic urine (p-U) could be ob-
tained only after ureteral obstruction was established. Therefore, the re-
sults for pelvic urine are only shown for the UUO group
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moieties of LCN2 in the serum and tissues, we examined
the glycopeptidase sensitivity of the LCN2 proteins in
representative tissues obtained from LPS-treated mice.
Similar to observations in urinary samples, the molecu-
lar weights of the LCN2 proteins from all examined tis-
sues shifted to lower values (approximately 20 kDa) after
PNGase F treatment (Fig. 4). However, in contrast to
urinary LCN2, Endo H was partially effective in releasing
N-glycan from the 22-kDa LCN2 in the liver and the
ureter, whereas this protein minimally cleaved the carbo-
hydrates on LCN2 from the sera, lungs, and kidneys of
LPS-treated mice (Fig. 4). NA treatment clearly affected
the LCN2 digestion in the serum and Endo H-resistant
tissues, such as the lung and the kidney, whereas it min-
imally influenced the size of LCN2 in Endo H-sensitive
tissues, such as the liver and the ureter of LPS-treated
mice. These results indicate that the sensitivities of LCN2
proteins to glycosidases differed between the urine and
certain tissues, and the LCN2 proteins secreted in the
serum and urine, as well as in the lungs and kidneys, of
LPS-treated mice mainly contain complex N-glycans.
The correlation between LCN2 and pro-inflammatory
markers
We then measured the levels of serum pro-inflammatory
markers, such as IL-1β, in our LPS-treated model to
evaluate the correlation of inflammatory responses with
the production of urinary LCN2 isoforms. In addition,
the effects of steroid pretreatment (Dex; 5 mg/kg) on the
LCN2 production following LPS treatment was investi-
gated. LPS administration (1 mg/kg i.p.) actively caused
systemic inflammation, which increased the serum CRP
levels in both the saline- and Dex-pretreated mice
(Fig. 5a, P < 0.001 for LPS treatment, P = 0.28 for Dex
treatment, and P = 0.42 for LPS × Dex treatment, by a
two-way ANOVA).
LPS increased the serum IL-1β level in the saline-
pretreated mice (Fig. 5b). In contrast, Dex pretreatment
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Fig. 3 Endo- and exoglycosidase digestions of urinary LCN2 from LPS-treated mice. (a) Proteins were subjected to SDS-PAGE and CBB staining.
Fetuin (48 kDa) served as a positive control substrate for PNGase F and NA, whereas RNase B (17 kDa) was the control substrate for Endo H. Each
experiment was repeated three times. The numbers on the right sides of the figures indicate the molecular marker size (kDa). (b) The N-glycosylation
sites of mouse urinary LCN2 were digested by PNGase F, Endo H, or NA. Each experiment was repeated six times. The numbers on the right
sides of the figures indicate the molecular size of LCN2 (kDa). (c) Comparison of the PNGase F digestions between recombinant mouse LCN2
(left and center) and native mouse urinary LCN2 (right). Each experiment was repeated three times. Protein samples (5 μg) and samples of conditioned
media (2 μL) were resolved by gel electrophoresis. The numbers on the right sides of the figures indicate the molecular size of LCN2 (kDa)
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suppressed the production of serum IL-1β upon LPS
exposure (Fig. 5b). Despite the effective suppression of
the serum IL-1β levels by Dex pretreatment, the serum
and urinary LCN2 levels were significantly increased
after LPS treatments (Fig. 5c and d). Thus, the upregula-
tion of LCN2 by LPS treatment correlated with pro-
inflammatory cytokine and CRP elevation, but the LCN2
production in our model could not be suppressed by pre-
treatment with 5 mg/kg Dex.
Discussion
The present study revealed that there are two distinct
types of urinary LCN2 isoforms that are induced after
LPS stimulation or UUO manipulation. The 24-kDa
urinary LCN2 was more glycosylated than the 22-kDa
form. Specifically, it contained an N-glycosyl side chain
that differed from the glycosylated 22-kDa LCN2 found
in the serum and peripheral tissues. Previous studies
also indicated that the urinary LCN2 can be separated
into several isoforms in animal models of drug-induced
kidney injury [31] and in mice with diabetic nephropa-
thy or ischemia-reperfusion injuries [9, 27]. Multiple
LCN2-immunopositive proteins have also been found
in conditioned media from human endometrial cancer
cell lines and in plasma samples from patients with
chronic myelogenous leukemia [37, 38]. Although the
differences in the two forms of LCN2 were not the re-
sult of glycosylation in the case of chronic myelogenous
leukemia [38], our results suggest that multiple glyco-
forms of urinary LCN2 can be generated by changing
the attached N-glycans. The previous studies and our
present works indicate that the inflammatory actions
associated with various diseases are significant events
leading to the production of multiple LCN2 forms.
Although LCN2 can bind siderophores to act as an iron
carrier, the differences in the molecular weight of LCN2
observed in urinary samples are not attributable to LCN2-
siderophore complexes because the molecular weight of a
siderophore in mammals is less than 1 kDa and the sid-
erophore binds to LCN2 in a 1:1 ratio [7, 39, 40].
Our results revealed that different tissues show differ-
ent distributions of LCN2 that are dependent on the in
vivo glycosylation patterns. Namely, 22-kDa LCN2 was
widely distributed throughout the body, including the
serum and urine, whereas the heavier 24-kDa form was
found in the bladder urine from the UUO model mice.
In general, circulatory LCN2 is filtered freely through
the glomerular membrane and is reabsorbed by proximal
tubular cells via the cell surface receptor, megalin [26].
In a mouse model of acute endotoxemia, LPS downregu-
lated the megalin receptor expression [41], suggesting
that there was failed reabsorption by the proximal tubu-
lar cells. In our present study, the estimated molecular
weight and glycosidase sensitivity were similar between
the urinary 22-kDa LCN2 and the serum LCN2. Thus,
the upregulation of urinary LCN2, especially 22-kDa
LCN2, could be partly attributed to the leakage of abun-
dant circulatory LCN2 due to the dysfunction of the re-
absorption mechanism resulting from megalin
downregulation. We also considered that the urinary 22-
kDa LCN2 might be directly secreted from the kidney,
ureter, and bladder due to its overexpression. However,
we only detected 24-kDa LCN2 in the urine, not in the
serum. This isoform may originate from the serum by
glomerular filtration, but its origin remains unclear. The
detailed mechanism(s) underlying the production of the
heavily glycosylated urinary 24-kDa LCN2 require fur-
ther study.
The distribution patterns of urinary 22- and 24-kDa
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Fig. 4 The glycosidase sensitivities of LCN2 in the serum and
peripheral tissues. LCN2 in the serum, lungs, kidneys, liver, and ureters
from LPS treated-mice was treated with endo- and exoglycosidases
(PNGase F, Endo H, and NA). Each experiment was repeated three
to five times, and 5 μg of protein was resolved by gel electrophoresis.
The numbers on the right sides of the figures indicate the molecular
size of LCN2 (kDa)
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obstruction model mice, suggesting that the emer-
gence of the two different glycosylated urinary LCN2
isoforms could differ according to the pathological
conditions. We hypothesize that the urinary 22-kDa
LCN2 accumulated around the obstructed renal pelvis
in our UUO mice was mainly derived from the dam-
aged kidney and injured ureter. Interestingly, ureteral
obstruction predominantly induced the 24-kDa LCN2
isoform in bladder urine, which was derived from the
unobstructed side of kidney and ureter. Ureteral ob-
struction can damage renal cortical tubular cells and
result in interstitial fibrosis due to macrophage infiltra-
tion, generating pro-inflammatory cytokines, such as
TNF-α, on the obstructed side of the kidney [42–44].
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Fig. 5 Dexamethasone pretreatment did not prevent the LPS-induced increase in LCN2. The serum and urinary LCN2 levels were examined after
pretreatment with a vehicle (saline) or dexamethasone (Dex, 5 mg/kg) 1 h prior to the administration of saline or LPS (1 mg/kg i.p.). The LPS
treatment significantly increased serum CRP (a) and IL-1β (b) levels. Dexamethasone pretreatment suppressed an increase of serum IL-1β, but
not of CRP. The serum (c) and urinary (d) LCN2 protein levels were significantly increased by LPS treatment (p < 0.05). However, Dex treatment did not
change the serum or urinary LCN2 levels. The values shown were the signal intensities relative to those of the samples from mice administered the ve-
hicle and saline. S, saline treatment; and L, LPS treatment. (n = 5) *, P <0.05 vs. saline
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Other cytokines, such as IL-1β or IL-17, which are
involved in stimulating Lcn2 gene expression, are also
induced by UUO [45, 46]. Thus, the urinary 24-kDa
LCN2 in the UUO model primarily arose from the dam-
aged ureter on the obstructed side. In humans, the level of
LCN2 is significantly higher in the bladder urine of pa-
tients with ureteropelvic junction obstruction (UJPO) than
in healthy subjects [47]. The glycoforms of LCN2 are thus
expected to be useful to identify urinary tract injuries,
such as UJPO.
The LCN2 isoforms detected in the mouse serum,
urine and some peripheral tissues were divided into two
types depending on their sensitivities to glycosidases.
We observed that there were differences between Endo
H and NA sensitivity in the carbohydrate moiety of
LCN2 in individual peripheral tissues. Namely, Endo H-
resistant and NA-sensitive LCN2 was detected in the
lungs and kidneys of the LPS-treated mice. Conversely,
in the livers and ureters of these mice, Endo H treatment
clearly cleaved the N-glycan of LCN2, whereas the mo-
bility of LCN2 after NA treatment was not changed.
Therefore, the N-linked carbohydrate moieties of LCN2
in the liver and ureter are predicted to have a high
mannose or hybrid-type content and a lower sialylated
N-glycan content than the Endo H-resistant LCN2,
such as the isoforms found in the lungs and kidneys. In
our experiments, the secreted LCN2 in the mouse serum
and urine contained the Endo-H-resistant and NA-
sensitive complex N-glycans, whereas Endo-H-sensitive
LCN2 could not be detected in the serum or urine of
LPS-treated mice.
The structure of N-glycan is involved in the apical
sorting of secretory glycoproteins in epithelial cells, and
removal of the terminal sialic acids from N-glycan leads
to a shorter plasma half-life for the glycoprotein [48, 49].
Therefore, carbohydrate moieties may regulate the extra-
cellular delivery or serum stability of LCN2 proteins.
Further investigations will help to clarify the structure of
N-glycan and the secretory properties of LCN2.
Conclusions
Our results indicate that LCN2 can exist in multiple gly-
cosylated forms, depending on the type of injury present
and the type of sample examined. For example, the more
glycosylated urinary LCN2 isoform could be useful for
predicting urinary tract obstruction. Further studies of
the glycoforms of LCN2 will provide valuable insight
into the correlation between the glycosylation of LCN2
and various pathological conditions.
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